acceptodds
Under review as a conference paper at ICLR 2027

AbEvolve: Aligning Protein Language Models with Preference Signals from Antibody Natural Selection

Abstract

While protein language models (PLMs) extract general biological syntax from sequence databases, they often exhibit an alignment gap in antibody engineering. This gap stems from antibodies' unique evolutionary search for optimal binding specificity—a logic that self-supervised PLMs trained on static sequence collections do not explicitly model, because the experimentally labeled data that would reveal this search directly are scarce and costly to produce. In this paper, we instead explore the large-scale, coarse redundancy signal that is readily available in unlabeled antibody sequencing data. To bridge this gap, we propose AbEvolve, a systematic framework that transforms the clonal abundance within antibody sequencing data—a coarse yet massive proxy for natural selection—into explicit abundance-derived evolutionary trajectories for PLM alignment training. By leveraging abundance as a proxy for natural selection, AbEvolve converts latent sequence distributions into actionable signals that help PLMs better capture maturation-associated sequence preferences. To absorb these signals, we adopt two alignment objectives—reward-weighted maximum-likelihood (RW-MLE), which reweights terminal variants by their abundance reward, and GFlowNet alignment, which propagates the scalar abundance rewards along constructed mutation paths and preserves intermediate path structure. We integrate AbEvolve with pre-trained models including ESM2 and ProteinReasoner and evaluate their zero-shot performance across representative antibody property prediction tasks. AbEvolve improves zero-shot ranking on all eight benchmarks—spanning binding, thermostability, and expression—for ESM2-GFlowNet; for ProteinReasoner, GFlowNet alignment improves binding and thermostability, whereas expression gains vary by benchmark. Together, AbEvolve offers a new supervision source and modeling pathway for addressing this alignment gap in therapeutic antibody design.

Primary area:
applications to physical sciences (physics, chemistry, biology, etc.)
Keywords:
Protein Language Models, Protein Optimization

Reviews

Among:
Shape:
1234this paper, Bottom 27%
Figure 1. Mean review rating of the reviewed papers at ICLR 2027. This paper averages 2.00 over 3 reviews, above 27% of the others.
Reviewer_UDxFOpenReview ↗
Rating
3
Confidence
3
Informativeness
2
Presentation
3
Soundness
3
Read review
Paper summary

AbEvolve introduces a framework for aligning protein language models with evolutionary selection signals extracted from natural antibody repertoires. The approach uses clonal abundance as a proxy for fitness and constructs mutation trajectories to train models through reward-weighted maximum likelihood and GFlowNet alignment. The authors demonstrate improved zero-shot prediction of antibody binding and thermostability across multiple benchmarks and model architectures.

Critical strengths

The central strength is the clever use of clonal abundance as an essentially free and massively scalable source of functional supervision. Although abundance is an imperfect proxy for fitness, the authors demonstrate that these noisy signals can meaningfully improve protein language models. The consistent improvements across multiple benchmarks and architectures, together with the ablation studies, provide encouraging support for the approach.

Critical weaknesses

My main concern is the interpretation of the reconstructed evolutionary trajectories. The inferred mutation order does not necessarily reflect actual evolutionary history, and it remains unclear how much additional information the GFlowNet approach captures beyond abundance-weighted sequence preferences. However, I do not consider this a fundamental limitation of the central contribution.

Questions for authors

Can the authors further clarify what additional information is captured by GFlowNet alignment compared with simpler preference-learning approaches? In particular, would a pairwise preference-learning objective using the same abundance-derived signals achieve similar improvements?

1 comment

We thank the reviewer. The concern and the question raise three points: whether the reconstructed order is an evolutionary history, what GFlowNet alignment adds beyond an abundance-weighted sequence preference, and whether a pairwise objective on the same abundance signal gives a similar improvement. The comparison of Trajectory Balance, path-level RW-MLE, and endpoint RW-MLE is in the comment Trajectory Balance versus a reward-weighted path likelihood. The pairwise result is the comment Response for DPO alignment.

1. The reconstructed order is not an evolutionary history.

FGMO orders substitutions by how often they occur in the lineage and inserts a virtual node when an intermediate is unobserved. On the 2.6K-lineage ablation, with the GFlowNet objective held fixed, FGMO is stronger than reverse-FGMO. We will describe it as a frequency heuristic of the construction, and we will explore better ways of building these trajectories in future work.

2. What GFlowNet adds beyond an abundance-weighted sequence preference.

The setup and the table are in the comment cited above. Path-level RW-MLE and endpoint RW-MLE use the same softmax weight. The gain comes from modeling the edited positions: the path loss applies that weight only to the edit steps, whereas the endpoint loss applies it to every token, including the background shared with the parent. The means are 0.362 and 0.327. Trajectory Balance, on the same fixed paths, reaches a similar mean to path-level RW-MLE (0.367 vs. 0.362). The flow-matching terms do not add a consistent further gain.

3. Would a pairwise objective give a similar improvement?

We thank the reviewer for suggesting DPO. The setting and the table are in the comment “Response for DPO alignment” . DPO can also emphasize the edited positions. The loss depends on the log-probability gap between the chosen and rejected sequences, so positions shared by the pair contribute little, and the update concentrates on the substitutions that distinguish them. This is a pairwise contrast rather than an explicit path, but it is the same reason the path objectives help: the abundance signal is applied to the edits instead of to the shared background. DPO reaches a similar eight-benchmark mean to the path objectives (0.362, versus 0.367 for TB and 0.362 for path-level RW-MLE). The gain is concentrated on binding, where DPO is the best of these objectives (mean 0.287, versus 0.263 for TB and 0.254 for endpoint RW-MLE).

Reviewer_9tguOpenReview ↗
Rating
2
Confidence
3
Informativeness
3
Presentation
3
Soundness
1
Read review
Paper summary

The authors argue that protein language models (PLMs) have an alignment gap in antibody engineering: 1) self-supervised training on static sequence collections captures broad evolutionary plausibility rather than the local, antigen-driven selection that governs affinity maturation, and 2) the experimental labels that would expose this selection directly are scarce and costly. To this end, the authors propose AbEvolve, a model-agnostic framework that converts clonal abundance in OAS—a coarse but massive proxy for natural selection—into explicit evolutionary trajectories for PLM alignment. Specifically, each clonal lineage is identified from OAS by V/J gene and CDR3 length followed by edit-distance clustering, and its lowest-abundance sequence is taken as a seed from which every other member receives a reward equal to its log-abundance gap, with the intervening substitutions ordered by lineage-level frequency (FGMO) into a mutation path. These trajectories are absorbed either by RW-MLE, which reweights the seed-conditioned terminal likelihood by the reward, or by GFlowNet alignment, which propagates the reward along the full path via lightweight forward and backward action heads on the pre-trained backbone. Through experiments on eight antibody property benchmarks spanning binding, thermostability, and expression with ESM2 and ProteinReasoner backbones, the authors demonstrate that AbEvolve improves zero-shot Spearman’s ρ over the vanilla backbones on all eight benchmarks for ESM2-GFlowNet and on binding and thermostability for ProteinReasoner.

Critical strengths
  1. The paper turns raw OAS repertoires into abundance-labeled mutation paths through a concrete and well-documented sequence of steps, and the resulting resource is independent of the alignment objective applied on top of it, so other work on antibody representation learning could adopt the construction without adopting RW-MLE or GFlowNet.

  2. The premise is well motivated: the gap between what self-supervised PLMs optimize and what antibody engineering requires is a recognized problem, and the observation that antibody-specific PLMs already train on OAS while discarding the redundancy counts attached to each sequence identifies a concrete and previously unexploited source of supervision.

Critical weaknesses
  1. GFlowNets are motivated by covering diverse high-reward modes, but that property comes from sampling trajectories, whereas FGMO fixes every path in advance and the policy never explores. It is unclear what Trajectory Balance contributes over a simpler reward-weighted path likelihood, and no such ablation is reported. Using the forward policy as a ranking function is more questionable still: terminal probabilities are calibrated to the training distribution, yet at evaluation the seed is a benchmark wild-type rather than a least-abundant lineage member.

  2. Table 5 reports that min-abundance seed selection collapses 2,600 lineages to 593 unique starting sequences, which the authors read as evidence that the sequence–redundancy association is load-bearing. The same number admits the opposite reading: if thousands of independent lineages converge on a few hundred starts, those starts are likely a specific class of sequence — plausibly germline-proximal ones, which the restoration step makes mutually similar by filling both termini from IMGT templates. If so, the trajectories run germline-to-mature in practice, and the claimed departure from phylogeny-based construction is weaker than stated. The SHM distance distribution of the 593 seeds would settle this and is not reported.

Questions for authors
  1. All evaluation is zero-shot. In practice a few measured variants for the target are usually available, and the relevant question is whether a better-aligned prior improves few-shot ranking or sample efficiency. Do the gains over vanilla backbones persist under light supervision?

  2. Section 2 groups preference-based alignment with methods needing target-specific assays, citing ProteinDPO, but DPO requires only preference pairs, which within-lineage abundance ordering supplies directly — no experimental labels are involved, so a DPO-aligned backbone would be evaluated zero-shot exactly as RW-MLE and GFlowNet are here. Given that RW-MLE uses abundance as an absolute weight and is unstable on several benchmarks, a pairwise objective seems a natural third comparison under the same protocol. Was it considered?

1 comment

We thank the reviewer. The two weaknesses and the two questions are separate, and we answer each below. The Trajectory Balance ablation is in the comment “Trajectory Balance versus a reward-weighted path likelihood.” The pairwise result is in the comment “Response for DPO alignment”.

1. What Trajectory Balance adds when the path is fixed.

We agree that FGMO fixes every path before training, so the policy does not sample alternative trajectories. The diverse-mode motivation of GFlowNets does not apply to this setup. The comment replaces the TB loss with a reward-weighted likelihood of the same path. Path-level RW-MLE has no backward policy and no partition function. On a fixed path the reverse step is already chosen, so the two fits move the forward policy in the same direction. The eight-benchmark means are 0.367 (TB) and 0.362 (path-level). The flow-matching terms do not add a consistent gain.

The gain over endpoint RW-MLE comes from where that weight is applied. Both use the same within-lineage softmax, Rˉ(si)=exp⁡(R(τi))/∑jexp⁡(R(τj))\bar{R}(\mathbf{s}_i)=\exp(R(\tau_i))/\sum_j\exp(R(\tau_j)). The endpoint loss multiplies it into every token, including the background shared with the parent. The path loss multiplies it only into the edit steps. The means are 0.362 (path-level) and 0.327 (endpoint). Where the two path objectives agree and the endpoint does not, the cause is this edit-only term, not Trajectory Balance.

At evaluation the seed is the benchmark parent, not the minimum-abundance training root. The score is the sum of forward-policy log-probabilities along the FGMO path from that parent. Candidates that share a parent are ranked against each other, so Spearman uses only that order. TB and path-level RW-MLE are scored the same way. We will state this shift in the scoring protocol.

2. Are the 593 starts germline-proximal?

The minimum-abundance sequence is an operational root, not a germline or an ancestor. Of 593 starts, 584 have a V-region distance to the annotated germline: amino-acid substitutions at IMGT positions 1–104, excluding CDR3. Heavy chain: 227 starts, median 9, mean 9.7, 13% with zero substitutions. Light chain: 357 starts, median 0, mean 1.4, 65% with zero substitutions. These are not nucleotide SHM counts. The reviewer’s reading fits the light chain, where template completion can also make truncated sequences share the germline termini. It does not fit the heavy chain, where a typical start is about ten substitutions away. We will not claim that these trajectories begin far from the germline. The drop from 2,600 lineages to 593 starts shows that abundance selects the root; the distances show which sequences that rule returns. We will report both.

3. Was a pairwise objective considered?

We thank the reviewer for suggesting it. Section 2 grouped preference alignment with methods that need target-specific assays. That grouping is wrong for this setting: within-lineage abundance order supplies the pairs, and no experimental labels are used. The DPO comment reports the construction and the table. DPO reaches a similar eight-benchmark mean to the path objectives (0.362, versus 0.367 for TB and 0.362 for path-level RW-MLE). Endpoint RW-MLE is the unstable case the reviewer pointed to: on Koenig2017 it falls to 0.127, below the vanilla backbone at 0.292, while DPO reaches 0.363. Pairwise learning is a real third use of the abundance ranking.

4. Do the gains persist under light supervision?

This is the practical question. We did run light-supervision fine-tuning, and we are not confident in the numbers. With about 20–100 labeled variants, the train–test split and the choice of checkpoint both move the per-seed Spearman, and different choices do not agree. We do not report a result we do not trust. Carrying out this fine-tuning with a split and a checkpoint rule we can stand behind is left to future work. The results in the paper are zero-shot.

Reviewer_ppUUOpenReview ↗
Rating
1
Confidence
3
Informativeness
2
Presentation
3
Soundness
1
Read review
Paper summary

In this work, the authors propose AbEvolve, a model-agnostic framework for pLM alignment with antibody evolution trajectories. They use abundance as a proxy for natural selection. They propose two frameworks trained on top of embeddings from two different protein language models (ESM2, ProteinReasoner). The RW-MLE framework reweights the final sequence variants by their abundance in the clonal pool whereas the GFlowNet alignment propagates the abundance rewards over a evolutionary trajectory. They test performance of their framework on zero-shot binding, thermostability and expression tasks. The GlowNet framework trained on ESM2/ProteinReasoner seems to outperform the pLM pseudo-log likelihood-based predictions.

Critical strengths
  1. The framework to map antibody evolution trajectories with GlowNets for pLM alignment is a novel strategy.
  2. The authors compare abundance weighting of the final sequence as the reward versus learning the order in which the sequences evolve. This is a very relevant experiment and should inform how antibody evolution trajectories must be leveraged.
Critical weaknesses
  1. Arbitrary evaluation on a subset of SKEMPI, baselines setup to fail – Only 18 targets with single mutations were selected from SKEMPI. This is about 10-20% of the overall non-redundant version of the dataset (ballpark figures). The choice of a single mutation is unclear. Using this arbitrary subset of skempi is misleading and disadvantages baselines. For example, for ESM2 and other PLM baselines, the authors average the plls over the entire sequence. An antibody sequence is approx. 220 residues on an average. A single mutation will lead to almost identical plls for the SKEMPI dataset. I also recommend that the authors report results on the full SKEMPI baseline unless they can justify the choice of the subset. Furthermore, ESM2 and other pLMs used as baselines in the paper should be evaluated on the pll on the edit site alone, not on the mean-pooled value over the entire sequence.

  2. Besides the issue noted with Skempi, the overall benchmark set chosen for this study is very limited and covers a very small set of antibody space. For example, the Koenig 2017 paper covers a single antibody (yes, with a large number of mutations but still only one-starting antibody/germline). I suggest that the authors consider using “FlAb” as a test set to generate more evidence for their proposed work.

  3. Baselines - The authors should add ProGen2 as a baseline. It is one the rare general pLMs which reports zero-shot performance on binding, expression and thermostability of antibodies. The ProGen2 reported performance metrics outperform the reported metrics here.

  4. Trajectory construction needs more work: I also think the abundance-based strategy that ignores the germline sequence is a mistake. A low-abundance sequence could be the result of somatic hypermutation event that does not improve binding. There is no reason why the sequence with lowest abundance should be at treated as the “source” of the evolutionary trajectory. Similarly, insertions and deletions within CDR loops can be treated as related sequences even though the overall sequence length changes. I think these choices are crucial and should have been tested thoroughly.

Questions for authors

It is unclear why the authors chose a very small subset of skempi.

2 comments

We thank the reviewer for the thoughtful comments. We address the concerns regarding SKEMPI curation, mutation scoring, benchmark coverage, and trajectory construction below.

SKEMPI curation and expanded evaluation

We followed the SKEMPI curation procedure described by AbDesign [1]: retaining antibody–antigen complexes with complete heavy and light chains and mutations on the antibody, and resolving duplicate measurements by prioritizing records with detailed kinetic data, more informative assay methods, and lower temperatures. We required at least five variants per seed to calculate per-seed Spearman correlations. The original single-mutant evaluation contained 18 seeds and 343 variants. We then added five eligible seeds containing multi-mutant records, resulting in an expanded set of 23 seeds and 468 variants (357 single mutants and 111 multi-mutants). All variants are amino-acid substitutions in VH or VL; none contains an insertion or deletion.

Full-sequence versus mutation-site scoring

Within each seed, candidates have the same sequence length. The full-sequence mean is therefore the full-sequence sum divided by a constant, so both give the same ranking and Spearman correlation. Scoring only the substituted site changes the ranking.

ModelFull-sequenceMutated siteSite log-odds
ESM2-650M0.0900.1120.143
AntiBERTy0.0880.0480.038
ProGen2-large0.090−0.002−0.042

These are macro-averaged per-seed Spearman correlations on the original 18-seed, 343-single-mutant set. Site log-odds is the substituted residue’s log probability minus the wild-type residue’s log probability in the same context. Mutation-site scoring does not improve all baselines. ProGen2 is reported on this original set; it has not been evaluated on the expanded set. The ESM2 rerun used bfloat16 and yielded 0.090, compared with 0.075 in the manuscript. We will report this difference without attributing it solely to precision.

On the expanded set, we calculate Spearman’s ρ\rho between model scores and −ΔΔG-\Delta\Delta G within each seed and report the unweighted mean across seeds:

ModelMean per-seed Spearman’s ρ\rho
ESM20.142
AntiBERTy−0.015
CoSiNE0.278
ProteinReasoner0.145
PR-GFlow0.223
PR-RW-MLE0.223
ESM-GFlow0.237

For ESM2, each mutated position is scored separately by masking that position in the wild-type sequence while leaving all other positions wild type. The variant score is the sum of these site-wise log-odds; it therefore does not model interactions between mutated sites. CoSiNE has the highest reported score on this set. We treat these as descriptive results and make no claims of statistical significance without uncertainty estimates or significance tests.

Starting sequences and germline distance

We agree that abundance alone cannot establish evolutionary ancestry. We use the minimum-abundance sequence as an operational starting point for constructing abundance-informed pseudo-trajectories, not as an asserted biological ancestor. A low-abundance sequence may carry a deleterious somatic mutation, so abundance alone cannot determine ancestry or the direction of evolution.

The submitted dataset contains 593 distinct starting sequences. We could calculate V-region germline distances for 584; six lacked a usable germline reference or alignment, and three did not have recoverable corresponding records in the available lineage files. The distances count amino-acid substitutions at IMGT positions 1–104 and exclude CDR3.

ChainScored startsMedian substitutionsMean substitutionsZero substitutions
Heavy22799.713%
Light35701.465%

These are amino-acid distances, not nucleotide-level SHM counts; zero substitutions does not establish that a sequence has never undergone SHM. Weighted by trajectory reuse, 83% of the 2,130 light-chain trajectories had zero substitutions in this V-region comparison. This describes the selected starts’ relationship to the annotated references but does not validate minimum abundance as an ancestry criterion.

For the 195 completed starts with scorable V regions, completion did not change the number of V-region substitutions. Their mean substitution rate decreased from 0.0768 to 0.0665 because template-matching residues increased the denominator. Completion can also map different truncated observations to the same completed sequence across files, but the available records do not let us quantify its effect on the 593 selected starts.

The existing abundance-shuffling comparison does not isolate the effect of starting-point selection because it changes both the selected starts and the lineage composition. We have not completed matched experiments comparing alternative starting-point rules. We will therefore avoid presenting the current results as evidence that minimum-abundance starts recover biological ancestry or are the optimal trajectory roots.

Indels and future work

Our current repertoire-processing pipeline filters sequences of different lengths, and the trajectory representation supports amino-acid substitutions but not insertions or deletions. We agree that this excludes potentially informative CDR-loop variants. We aim to develop methods that can extract evolutionary signals from large-scale, noisy repertoire data while better handling indels. This is an important direction for addressing the shortage of antibody training data.

[1] AbDesign: Database of point mutants of antibodies with associated structures reveals poor generalization of binding predictions from machine learning models; AbDesign website.

Comments on the paper

2 comments
AuthorsOpenReview ↗

Response for DPO alignment

We thank reviewers for raising the question of whether the abundance signal can also be used as a preference signal. We additionally train ProteinReasoner-DPO on the full set of 260K OAS clonal lineages. Within each lineage, candidates are ranked by the abundance-derived reward. The top 25% form the chosen pool and the remaining candidates form the rejected pool. Rewards are normalized by within-lineage rank into [0,1][0,1], one pair is sampled per seed, and a pair is retained only when the chosen–rejected gap is at least 0.5 normalized-rank units.

The policy is ProteinReasoner-650M, conditioned on the same seed sequence, structure tokens, and MSA profile as in the main experiments. The reference model is a frozen copy of the same initialization, with β=0.1\beta=0.1. Training uses AdamW with learning rate 10−410^{-4}, weight decay 0.01, and an effective batch size of 128 preference pairs. The model is trained for one epoch on the full approximately 260K-lineage set. All results use the same zero-shot evaluation protocol as the main experiments.

BenchmarkPR-DPOPR-GFlowNetPR-RW-MLEPR-VanillaCoSINE
SKEMPI-V20.3020.2570.2650.0190.290
AB-Bind0.3000.2730.2450.1880.196
IgDesign0.2600.2580.2520.2110.203
Hutchinson20230.3470.4050.3610.2080.379
BC-T07 stability0.5300.6350.5600.6070.474
Koenig20170.3630.4130.1270.2920.494
BC-T07 expression0.4870.4200.4610.3990.438
Adam20170.3080.2750.3430.4250.404

DPO improves all three binding benchmarks over both ProteinReasoner-GFlowNet and ProteinReasoner-RW-MLE. It also outperforms CoSINE on all three binding benchmarks, as well as on both BC-T07 subsets. Overall, DPO performs better than CoSINE on five of the eight benchmarks, while CoSINE remains stronger on Hutchinson2023, Koenig2017, and Adam2017. These results show that the abundance-derived ranking can be effectively converted into pairwise preferences and learned through DPO. We will include the full preference-pair construction, training configuration, and per-benchmark results in the paper.

AuthorsOpenReview ↗

Trajectory Balance versus a reward-weighted path likelihood

We thank reviewers for asking what GFlowNet alignment adds beyond a simpler use of the same abundance signal. One request is the comparison between Trajectory Balance and a reward-weighted likelihood of the same FGMO path, which is fixed before training. We report that comparison here.

Experimental control. FGMO fixes every training path before learning, so the policy does not sample alternative trajectories. We keep the ProteinReasoner backbone, the FGMO paths, the abundance reward, and the forward-policy scoring rule fixed, and replace the TB loss with path-level RW-MLE. Path-level RW-MLE reweights the forward path log-likelihood by the within-lineage softmax weight, Rˉ(si)=exp⁡(R(τi))/∑jexp⁡(R(τj))\bar{R}(\mathbf{s}_i)=\exp(R(\tau_i))/\sum_j\exp(R(\tau_j)), the same weight used for endpoint RW-MLE. It has no backward policy and no partition function. It has no backward policy and no partition function. The TB column is ProteinReasoner-GFlowNet from the submitted table. Evaluation is the same zero-shot protocol.

Results.

BenchmarkTBPath-level RW-MLEEndpoint RW-MLE
SKEMPI-V20.2570.2410.265
AB-Bind0.2730.1850.245
IgDesign0.2580.2650.252
Hutchinson20230.4050.3580.361
BC-T07 thermostability0.6350.6530.560
Koenig20170.4130.4550.127
BC-T07 expression0.4200.4330.461
Adam20170.2750.3070.343
Mean0.3670.3620.327

What TB adds on a fixed path. TB and path-level RW-MLE see the same FGMO paths and the same abundance reward. The difference is the fit. TB matches the log forward-path probability to the log reward, in a squared residual that also contains the backward policy and a partition function. Path-level RW-MLE weights that forward log-probability by this softmax weight. On a path FGMO has already chosen, the reverse step is the constructed step, so the backward policy has little further choice. Both fits therefore move the forward policy the same way, toward higher probability for higher-reward paths. The zero-shot rankings come out close. TB and the reward-weighted path likelihood transfer this abundance signal to a similar degree.

Path likelihood versus endpoint RW-MLE. Path-level RW-MLE and endpoint RW-MLE use the same weight. In both losses the scalar is the within-lineage softmax of the terminal abundance gap, Rˉ(si)=exp⁡(R(τi))/∑jexp⁡(R(τj))\bar{R}(\mathbf{s}_i)=\exp(R(\tau_i))/\sum_j\exp(R(\tau_j)). The weight multiplies a different log-probability: the sum of forward-step log-probabilities along the FGMO path, or the full-sequence log-likelihood of the terminal.

That gap is large relative to the TB comparison above. The eight-benchmark means are 0.362 (path-level) and 0.327 (endpoint), a signed difference of +0.035, against 0.033 between TB and path-level RW-MLE.

The mechanism is the support of the weighted term. The endpoint loss multiplies Rˉ\bar{R} into every token of the terminal, including residues the variant shares with its parent, so a high-weight sequence raises its background as well as its mutations. The path loss multiplies the same Rˉ\bar{R} only into the edit steps.

From OpenReview, CC BY 4.0. Authors as signed there; shown unedited.

Related papers

Loading the map…

Discussion (0)

Sign in to comment.